GERMANTOWN, Md. – Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of transformative glucose monitoring products, has announced a collaboration with TypeZero Technologies, Inc., a personalized diabetes management company, and Roche Diabetes Care, Inc., a global leader for diabetes management systems and services, to develop a long-term automated insulin delivery system. The collaboration is part of the National Institutes of Health-funded International Diabetes Closed Loop Trial, which was designed to test automated insulin delivery systems. “This partnership is an example of how industry, research and clinical care work together to move innovative technologies from research to development and then to patients to minimize the burden of diabetes,” said Boris Kovatchev, principal investigator of IDCL Trial. This phase of the IDCL Trial will integrate Senseonics’ Eversense CGM system with TypeZero’s inControl AP algorithms and Roche’s Accu-Chek Insight Insulin Pump. The inControl software will automatically adjust and regulate insulin delivery based on the combination of data received from the CGM system and the insulin pump. The trial will include three clinical centers in Europe—the University of Amsterdam in the Netherlands, the University of Padova in Italy and University Hospital of Montpellier in France.
You are here: / / Collaboration to test closed-loop system